Alzheimer’s & Dementia

Filter Your Results




Another Beta-Secretase 1 (BACE) Inhibitor Phase 3 Trial Stopped

Wednesday, November 07, 2018—A trial of investigational drugs LY3202626 and LY3002813 (also known as N3pG mAB) (BACE IV; Eli Lilly, Indianapolis, IN) in combination for patients with Alzheimer’s dis…

Positive Top-Line Results Announced from Phase 2 Study of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder

Tuesday, October 30, 2018—Pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA), already approved for treatment of patients with Parkinson’s disease (PD) psychosis is also being studied …

Evidence Growing That Eyes May Be A Window to Alzheimer’s Diagnosis

Monday, October 29, 2018—Results presented at the 122ndAnnual Meeting of the American Academy of Ophthalmology suggest that optical coherence tomography (OCT) and OCT-angiography (OCTA) may be diagnos…

Positive Preliminary Phase 2 Clinical Trial Results for Bryostatin as Treatment for Alzheimer’s Disease

Wednesday, October 24, 2018—At the 11thEdition of Clinical Trials on Alzheimer’s Disease (CTAD) interim results were shared from a phase 2 trial (NCT03560245) evaluating the use of bryostatin (Neur…

Correlation of Higher Cortisol Levels, Cognitive Deficits, and Lower Brain Volume Varies by Sex

Wednesday, October 24, 2018—In a study published in today’s issue of Neurology, data from participants in the Framingham Heart study (generation 3) identified a correlation among high blood co…

Hometown Highlights: Introducing Hometown Highlights

Stephen M. Gollomp, MD

October 2018—In this new column, we feature content from presenters at the 2018-2019 Philadelphia Neurological Society meetings.

Alzheimer’s Drug Discovery Foundation Meeting Reports Advances

Friday, September 21, 2018—At the 19th International Conference on Alzheimer’s Drug Discovery, the focus was on gene therapy and alternative modalities for treating patients with neurodegenerative…

FDA Analysis Finds No New or Unexpected Safety Risks of Pimavanserin:Benefits Outweigh Risks

Thursday, September 20, 2018—The Food and Drug Administration (FDA) announced that there are no new safety concerns for pimavanserin (Nuplazid; Acadia Pharma, San Diego, CA). Pimavanserin is approved for …


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.